Cytogenetic Abnormalities and Their Impact on Acute Myeloid Leukemia Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single‐Center Retrospective Study
ABSTRACT Background and Aims Cytogenetic abnormalities at diagnosis are detected in over half of adult patients with acute myeloid leukemia (AML). This study aimed to evaluate the impact of these abnormalities on the outcomes of AML patients undergoing allogeneic hematopoietic stem cell transplantat...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | Health Science Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/hsr2.70914 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850121347416457216 |
|---|---|
| author | Amir Abbas Rashidi Amir Kasaeian Kamran Alimoghadam Maryam Noori Hediyeh Alemi Ghazal Seghatoleslami Oveis Salehi Ardeshir Ghavamzadeh Mohammad Vaezi Seyed Asadollah Mousavi Hossein Kamranzadeh Davood Babakhani Soroush Rad Maryam Barkhordar Sahar Tavakoli Shiraji Marjan Yaghmaie |
| author_facet | Amir Abbas Rashidi Amir Kasaeian Kamran Alimoghadam Maryam Noori Hediyeh Alemi Ghazal Seghatoleslami Oveis Salehi Ardeshir Ghavamzadeh Mohammad Vaezi Seyed Asadollah Mousavi Hossein Kamranzadeh Davood Babakhani Soroush Rad Maryam Barkhordar Sahar Tavakoli Shiraji Marjan Yaghmaie |
| author_sort | Amir Abbas Rashidi |
| collection | DOAJ |
| description | ABSTRACT Background and Aims Cytogenetic abnormalities at diagnosis are detected in over half of adult patients with acute myeloid leukemia (AML). This study aimed to evaluate the impact of these abnormalities on the outcomes of AML patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) in an Iranian cohort. Methods This retrospective study included 206 AML patients aged over 15 who underwent allogeneic HSCT at a single center. Cytogenetic abnormalities were identified from medical records, and survival outcomes, including overall survival (OS) and leukemia‐free survival (LFS), were assessed across different cytogenetic risk groups. Multivariable analyses were adjusted for age, sex, donor type, time from diagnosis to transplant, and disease status at transplant. Results The median follow‐up duration was 46.75 months. 1‐, 3‐, and 5‐year OS rates were 80.0%, 65.9%, and 58.5%, respectively, with significant differences based on cytogenetic risk. Patients with −7, 7q abnormalities, +8, complex karyotype, and monosomal karyotype exhibited shorter OS, classifying them as adverse‐risk. Patients with normal karyotype, inversion (16), and t(16;16) were intermediate‐risk. LFS at 1, 3, and 5 years was 74.6%, 64.5%, and 54.1%, respectively, with adverse cytogenetic profiles significantly associated with shorter LFS. Conclusions This study demonstrates the prognostic significance of cytogenetic profiles in Iranian AML patients post‐HSCT. Results underscore the importance of cytogenetic stratification in guiding treatment decisions, suggesting that risk‐adapted guidelines may benefit specific populations. Future prospective studies on survival outcomes in Iranian AML patients could refine evidence‐based treatment guidelines. |
| format | Article |
| id | doaj-art-82a822fc6eaf42a88a617a842cdcbbdb |
| institution | OA Journals |
| issn | 2398-8835 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Health Science Reports |
| spelling | doaj-art-82a822fc6eaf42a88a617a842cdcbbdb2025-08-20T02:35:07ZengWileyHealth Science Reports2398-88352025-06-0186n/an/a10.1002/hsr2.70914Cytogenetic Abnormalities and Their Impact on Acute Myeloid Leukemia Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single‐Center Retrospective StudyAmir Abbas Rashidi0Amir Kasaeian1Kamran Alimoghadam2Maryam Noori3Hediyeh Alemi4Ghazal Seghatoleslami5Oveis Salehi6Ardeshir Ghavamzadeh7Mohammad Vaezi8Seyed Asadollah Mousavi9Hossein Kamranzadeh10Davood Babakhani11Soroush Rad12Maryam Barkhordar13Sahar Tavakoli Shiraji14Marjan Yaghmaie15Hematology, Oncology and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital Tehran University of Medical Sciences Tehran IranLiver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute Tehran University of Medical Sciences Tehran IranCell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology, and Cell Therapy Tehran University of Medical Sciences Tehran IranHematology, Oncology and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital Tehran University of Medical Sciences Tehran IranHematology, Oncology and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital Tehran University of Medical Sciences Tehran IranStudent Research Committee, Faculty of Medicine Mashhad University of Medical Sciences Mashhad IranHematology, Oncology and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital Tehran University of Medical Sciences Tehran IranHematology, Oncology and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital Tehran University of Medical Sciences Tehran IranHematology, Oncology and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital Tehran University of Medical Sciences Tehran IranCell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology, and Cell Therapy Tehran University of Medical Sciences Tehran IranHematologic Malignancies Research Center Research Institute for Oncology, Hematology and Cell Therapy Tehran University of Medical Sciences Tehran IranHematology, Oncology and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital Tehran University of Medical Sciences Tehran IranHematology, Oncology and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital Tehran University of Medical Sciences Tehran IranCell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology, and Cell Therapy Tehran University of Medical Sciences Tehran IranHematologic Malignancies Research Center Research Institute for Oncology, Hematology and Cell Therapy Tehran University of Medical Sciences Tehran IranHematology, Oncology and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital Tehran University of Medical Sciences Tehran IranABSTRACT Background and Aims Cytogenetic abnormalities at diagnosis are detected in over half of adult patients with acute myeloid leukemia (AML). This study aimed to evaluate the impact of these abnormalities on the outcomes of AML patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) in an Iranian cohort. Methods This retrospective study included 206 AML patients aged over 15 who underwent allogeneic HSCT at a single center. Cytogenetic abnormalities were identified from medical records, and survival outcomes, including overall survival (OS) and leukemia‐free survival (LFS), were assessed across different cytogenetic risk groups. Multivariable analyses were adjusted for age, sex, donor type, time from diagnosis to transplant, and disease status at transplant. Results The median follow‐up duration was 46.75 months. 1‐, 3‐, and 5‐year OS rates were 80.0%, 65.9%, and 58.5%, respectively, with significant differences based on cytogenetic risk. Patients with −7, 7q abnormalities, +8, complex karyotype, and monosomal karyotype exhibited shorter OS, classifying them as adverse‐risk. Patients with normal karyotype, inversion (16), and t(16;16) were intermediate‐risk. LFS at 1, 3, and 5 years was 74.6%, 64.5%, and 54.1%, respectively, with adverse cytogenetic profiles significantly associated with shorter LFS. Conclusions This study demonstrates the prognostic significance of cytogenetic profiles in Iranian AML patients post‐HSCT. Results underscore the importance of cytogenetic stratification in guiding treatment decisions, suggesting that risk‐adapted guidelines may benefit specific populations. Future prospective studies on survival outcomes in Iranian AML patients could refine evidence‐based treatment guidelines.https://doi.org/10.1002/hsr2.70914acute myeloid leukemiaallogeneic hematopoietic stem cell transplantationchromosome aberrationscytogenetic abnormalitiesprognostics |
| spellingShingle | Amir Abbas Rashidi Amir Kasaeian Kamran Alimoghadam Maryam Noori Hediyeh Alemi Ghazal Seghatoleslami Oveis Salehi Ardeshir Ghavamzadeh Mohammad Vaezi Seyed Asadollah Mousavi Hossein Kamranzadeh Davood Babakhani Soroush Rad Maryam Barkhordar Sahar Tavakoli Shiraji Marjan Yaghmaie Cytogenetic Abnormalities and Their Impact on Acute Myeloid Leukemia Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single‐Center Retrospective Study Health Science Reports acute myeloid leukemia allogeneic hematopoietic stem cell transplantation chromosome aberrations cytogenetic abnormalities prognostics |
| title | Cytogenetic Abnormalities and Their Impact on Acute Myeloid Leukemia Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single‐Center Retrospective Study |
| title_full | Cytogenetic Abnormalities and Their Impact on Acute Myeloid Leukemia Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single‐Center Retrospective Study |
| title_fullStr | Cytogenetic Abnormalities and Their Impact on Acute Myeloid Leukemia Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single‐Center Retrospective Study |
| title_full_unstemmed | Cytogenetic Abnormalities and Their Impact on Acute Myeloid Leukemia Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single‐Center Retrospective Study |
| title_short | Cytogenetic Abnormalities and Their Impact on Acute Myeloid Leukemia Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single‐Center Retrospective Study |
| title_sort | cytogenetic abnormalities and their impact on acute myeloid leukemia outcomes following allogeneic hematopoietic stem cell transplantation a single center retrospective study |
| topic | acute myeloid leukemia allogeneic hematopoietic stem cell transplantation chromosome aberrations cytogenetic abnormalities prognostics |
| url | https://doi.org/10.1002/hsr2.70914 |
| work_keys_str_mv | AT amirabbasrashidi cytogeneticabnormalitiesandtheirimpactonacutemyeloidleukemiaoutcomesfollowingallogeneichematopoieticstemcelltransplantationasinglecenterretrospectivestudy AT amirkasaeian cytogeneticabnormalitiesandtheirimpactonacutemyeloidleukemiaoutcomesfollowingallogeneichematopoieticstemcelltransplantationasinglecenterretrospectivestudy AT kamranalimoghadam cytogeneticabnormalitiesandtheirimpactonacutemyeloidleukemiaoutcomesfollowingallogeneichematopoieticstemcelltransplantationasinglecenterretrospectivestudy AT maryamnoori cytogeneticabnormalitiesandtheirimpactonacutemyeloidleukemiaoutcomesfollowingallogeneichematopoieticstemcelltransplantationasinglecenterretrospectivestudy AT hediyehalemi cytogeneticabnormalitiesandtheirimpactonacutemyeloidleukemiaoutcomesfollowingallogeneichematopoieticstemcelltransplantationasinglecenterretrospectivestudy AT ghazalseghatoleslami cytogeneticabnormalitiesandtheirimpactonacutemyeloidleukemiaoutcomesfollowingallogeneichematopoieticstemcelltransplantationasinglecenterretrospectivestudy AT oveissalehi cytogeneticabnormalitiesandtheirimpactonacutemyeloidleukemiaoutcomesfollowingallogeneichematopoieticstemcelltransplantationasinglecenterretrospectivestudy AT ardeshirghavamzadeh cytogeneticabnormalitiesandtheirimpactonacutemyeloidleukemiaoutcomesfollowingallogeneichematopoieticstemcelltransplantationasinglecenterretrospectivestudy AT mohammadvaezi cytogeneticabnormalitiesandtheirimpactonacutemyeloidleukemiaoutcomesfollowingallogeneichematopoieticstemcelltransplantationasinglecenterretrospectivestudy AT seyedasadollahmousavi cytogeneticabnormalitiesandtheirimpactonacutemyeloidleukemiaoutcomesfollowingallogeneichematopoieticstemcelltransplantationasinglecenterretrospectivestudy AT hosseinkamranzadeh cytogeneticabnormalitiesandtheirimpactonacutemyeloidleukemiaoutcomesfollowingallogeneichematopoieticstemcelltransplantationasinglecenterretrospectivestudy AT davoodbabakhani cytogeneticabnormalitiesandtheirimpactonacutemyeloidleukemiaoutcomesfollowingallogeneichematopoieticstemcelltransplantationasinglecenterretrospectivestudy AT soroushrad cytogeneticabnormalitiesandtheirimpactonacutemyeloidleukemiaoutcomesfollowingallogeneichematopoieticstemcelltransplantationasinglecenterretrospectivestudy AT maryambarkhordar cytogeneticabnormalitiesandtheirimpactonacutemyeloidleukemiaoutcomesfollowingallogeneichematopoieticstemcelltransplantationasinglecenterretrospectivestudy AT sahartavakolishiraji cytogeneticabnormalitiesandtheirimpactonacutemyeloidleukemiaoutcomesfollowingallogeneichematopoieticstemcelltransplantationasinglecenterretrospectivestudy AT marjanyaghmaie cytogeneticabnormalitiesandtheirimpactonacutemyeloidleukemiaoutcomesfollowingallogeneichematopoieticstemcelltransplantationasinglecenterretrospectivestudy |